Skip to content

Serum or Plasma Free Light Chain Immunoassay (kappa and lambda)

Published: August 9, 2026Updated: August 16, 2026

This test measures the free kappa and lambda light chains in your blood, which are small protein fragments produced by white blood cells. It helps diagnose conditions like multiple myeloma, lymphoma, or other blood disorders.

Quick summary

["Light chains can indicate abnormal immune system activity or cancer."]

Medically reviewed by WellAlly Editorial TeamLast reviewed August 16, 2026Editorial policy

Key facts at a glance

LOINC
18044-8
Short code
LV EF US.2D+SP-EL
Synonyms
LV EF US.2D+SP-EL
Category
chemistry
Sample
serum
Container
Red-top tube (SST)
Units
N/A
Fasting
false
Population
adult
Sex
all
Age range
18–65 years
Method
us-d-calculated-by-single-plane-ellipse-method
Specimen volume
5 mL
Stability
Room temperature: 4h, Refrigerated: 24h, Frozen: 7d
Hemolysis max
500
Lipemia max
1000
Icterus max
500
TAT
4–24 hours
Order
routine

Why Is This Test Done?

Your healthcare provider may order this test if you have symptoms like unexplained fatigue, weight loss, frequent infections, or swollen lymph nodes. It’s also used to monitor conditions like multiple myeloma, where abnormal plasma cells produce too many light chains.

What to Expect Before the Test

No special preparation is needed. You may have a small needle inserted into a vein (usually in your arm) to draw blood. If you’re on blood thinners, let your provider know before the test.

What the Results Mean

High levels of free light chains can signal multiple myeloma or other blood cancers. Low or normal levels don’t necessarily mean you’re healthy, but they may help rule out certain disorders. Results are interpreted by your doctor in the context of your symptoms and medical history.

Common Conditions This Test Helps Diagnose

This test is often used to diagnose or monitor multiple myeloma, lymphoma, or other plasma cell dyscrasias (abnormalities in blood cells). It can also help detect conditions like monoclonal gammopathy of undetermined significance (MGUS), a precursor to myeloma.

Clinical interpretation

How abnormal results are interpreted and what conditions they suggest.

Clinical Significance: Light chains are fragments of heavy chains produced by plasma cells. When these cells become cancerous (e.g., in multiple myeloma), they release excessive free light chains into the blood. Elevated levels can indicate cancer progression, while monitoring helps track treatment effectiveness.

Short name

Free Light Chain Test

Frequently asked questions

What does an abnormal result mean?
An abnormal result—especially high levels of kappa or lambda light chains—may suggest a blood disorder like multiple myeloma or lymphoma. Your doctor will review your full medical picture and may recommend further testing.
Can diet or medications affect this test?
Some medications (like steroids or chemotherapy) may influence light chain levels, but diet typically doesn’t. Always inform your provider about all medications or supplements you’re taking.
How often is this test repeated?
Frequency depends on your condition. If you have a blood disorder, your doctor may order this test regularly to monitor changes in your light chain levels over time.
  1. 1
  2. 2
  3. 3

Click any link to access the full source. PubMed Central (PMC) links provide free full-text access.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 16, 2026. · Read our editorial policy